Feline calicivirus (ATCC® VR-2057)

Classification: Caliciviridae, Vesivirus  /  Product Format: frozen

Classification Caliciviridae, Vesivirus
Agent Feline calicivirus
Strain FCV-2280
Applications
The virus is not neutralized by FCV-M8 antisera.
Biosafety Level 2
Isolation
blood - animal
Product Format frozen
Storage Conditions -70°C or colder (or colder)
Comments
The virus is not neutralized by FCV-M8 antisera. This virus has been adapted to tissue culture propagation, and may not readily infect cats.
Effect on Host
Yes, in vitro effects: CPE, cell rounding and sloughing
CPE, cell rounding and sloughing
Yes, in vivo effects: transient fever, oral vesicles, soreness
Growth Medium Minimum essential medium (Eagle) with 2 mM L-glutamine and Earle's BSS adjusted to contain 1.5 g/L sodium bicarbonate, 0.1 mM non-essential amino acids, and 1.0 mM sodium pyruvate, 98%; fetal bovine serum, 2%
Recommended Host
Felis catus
cat

Recommended Host: Fcwf-4 (ATCC® CRL-2787™)

Growth Conditions
Atmosphere: 5% CO2 in air recommended
Temperature: 37.0°C
Duration: In vitro: incubate 3 to 4 days. For best results cells should be 24 to 48 hours old and 70-80% confluent (not 100% confluent). In vivo: 3 to 4 days after oral inoculation.
Cryopreservation
Storage temperature: -70°C
Effect on Host
Yes, in vitro effects: CPE, cell rounding and sloughing
CPE, cell rounding and sloughing
Yes, in vivo effects: transient fever, oral vesicles, soreness
Name of Depositor University of California, Davis
Special Collection Patent
Source
blood - animal
References

Pedersen NC. Feline calicivirus vaccine. US Patent 4,522,810 dated Jun 11 1985

or colder

blood from naturally infected cat

or colder